EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant

Maartje A C Schreurs, Muriel A Adank, Bernadette A M Heemskerk-Gerritsen, Antoinette Hollestelle, Nyrée Smallenbroek, Christi J van Asperen, Margreet G E M Ausems, Irma van de Beek, Geertruida H de Bock, Ingrid Boere, Liselotte P van Hest, Kim J A F van Kaam und 6 weitere

The Breast · 2026

DOI: 10.1016/j.breast.2025.104666 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Breast, 2026. Verfasst von Maartje A C Schreurs und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Checkpoint Kinase 2, Breast Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Germline CHEK2 c.1100delC-associated breast cancer (BC) patients have been reported with worse prognosis than patients without the variant. However, results are based on older cohorts and treatment regimens. As part of the Hebon-CHEK2 study, we aim to study prognosis in a Dutch cohort of genetically tested ER-positive BC patients diagnosed from 2006 onwards. METHODS: All patients underwent genetic testing based on personal and family history risk, and data on BC outcomes were collected. Hazard ratios (HRs) and 95 % confidence intervals (CI) for the association of CHEK2-status with prognosis were estimated via delayed entry Cox regression models, adjusted for age and year of diagnosis, tumor size, nodal status, and primary treatment regimens. Furthermore, we meta-analyzed our results with previous studies. RESULTS: We included 480 CHEK2 BC patients and 944 BC patients without the variant. Median follow-up was 6.0 years. Heterozygotes were more often diagnosed with small tumors, and lymph node positive disease. No significant difference was found for recurrent disease and distant disease-free survival, neither before 5 years (HR = 0.73; 95 %CI = 0.35-1.53 and HR = 0.99; 95 %CI = 0.44-2.21, respectively), nor after 5 years follow-up (HR = 0.29; 95 %CI = 0.06-1.28 and HR = 0.39; 95 %CI = 0.10-1.39, respectively). Also no significant difference in BC-specific survival (HR = 0.77; 95 %CI = 0.42-1.39) or overall survival (HR = 0.69; 95 %CI = 0.43-1.08) was found. Meta-analysis of our results with previous studies showed a worse BC-specific survival for heterozygotes. CONCLUSION: In our study, with more recent years of diagnosis and treatment, we found no difference in prognosis, as opposed to previous studies. Further research is needed to validate our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Checkpoint Kinase 2Breast NeoplasmsHumansFemaleMiddle AgedPrognosisAdultReceptors, EstrogenAgedNetherlandsDisease-Free SurvivalGerm-Line MutationProportional Hazards ModelsGenetic TestingHeterozygote

Stichwörter der Autor:innen

Breast cancer outcomesCHEK2 c.1100delCER-Positive breast cancerPrognosis

Substanzen

Checkpoint Kinase 2CHEK2 protein, humanReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Clinical Genetics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.
  • Division of Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Human Genetics, Section Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Förderung

  • Dutch Cancer Society

Zitieren

APA

Schreurs, M. A. C., Adank, M. A., Heemskerk-Gerritsen, B. A. M., Hollestelle, A., Smallenbroek, N., van Asperen, C. J., Ausems, M. G. E. M., van de Beek, I., de Bock, G. H., Boere, I., van Hest, L. P., van Kaam, K. J. A. F., de Munck, L., Vos, J. R., Jager, A., Schmidt, M. K., Hooning, M. J., & Hebon (2026). Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant. The Breast. https://doi.org/10.1016/j.breast.2025.104666

Vancouver

Schreurs MAC, Adank MA, Heemskerk-Gerritsen BAM, Hollestelle A, Smallenbroek N, van Asperen CJ, et al. Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant. The Breast. 2026. doi:10.1016/j.breast.2025.104666

BibTeX
@article{Schreurs2026,
  author = {Schreurs, Maartje A C and Adank, Muriel A and Heemskerk-Gerritsen, Bernadette A M and Hollestelle, Antoinette and Smallenbroek, Nyrée and van Asperen, Christi J and Ausems, Margreet G E M and van de Beek, Irma and de Bock, Geertruida H and Boere, Ingrid and van Hest, Liselotte P and van Kaam, Kim J A F and de Munck, Linda and Vos, Janet R and Jager, Agnes and Schmidt, Marjanka K and Hooning, Maartje J and Hebon, Hebon},
  title = {Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant},
  journal = {The Breast},
  year = {2026},
  doi = {10.1016/j.breast.2025.104666}
}
Kostenlos starten →